Home » Stocks » CRSP

CRISPR Therapeutics AG (CRSP)

Stock Price: $122.27 USD -2.50 (-2.00%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $122.69 +0.42 (0.34%) Jul 23, 7:59 PM
Market Cap 9.74B
Revenue (ttm) 1.10M
Net Income (ttm) -392.30M
Shares Out 80.32M
EPS (ttm) -5.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $122.27
Previous Close $124.77
Change ($) -2.50
Change (%) -2.00%
Day's Open 124.50
Day's Range 119.39 - 124.64
Day's Volume 1,048,585
52-Week Range 76.71 - 220.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

It's already well on its way, but the road ahead will be long.

4 hours ago - The Motley Fool

On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look forward to the company's advancement with its lead gene-editing candidate CTX001.

20 hours ago - Zacks Investment Research

The company is on track to be the first to market with a gene-editing therapy for blood disorders.

1 day ago - The Motley Fool

Crispr Therapeutics isn't without risks, but that shouldn't dissuade investors from a CRSP stock collar purchase for core positioning. The post Crispr Therapeutics Has Bullish DNA appeared first on Inve...

1 day ago - InvestorPlace

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 days ago - Zacks Investment Research

While the technologies that undergird CRSP stock is nothing short of mind-blowing, you should be aware of the ethical risks. The post Can CRISPR Therapeutics Stock Investors Steer Clear of Ethical Conce...

5 days ago - InvestorPlace

CRISPR Therapeutics AG (CRSP) closed at $126.25 in the latest trading session, marking a -0.67% move from the prior day.

1 week ago - Zacks Investment Research

After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

Other stocks mentioned: BEAM, EDIT
1 week ago - The Motley Fool

Gene editing could revolutionize the way we treat diseases. Along the way, it could also create substantial opportunity for related stocks.

Other stocks mentioned: EDIT, NTLA
1 week ago - InvestorPlace

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

Other stocks mentioned: ARKG, BEAM, EDIT, GNOM, IDNA, NTLA, PBE
2 weeks ago - Zacks Investment Research

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year befor...

2 weeks ago - Forbes

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.

Other stocks mentioned: ALNY, BEAM, BNTX, EDIT, MRNA, NTLA
3 weeks ago - The Motley Fool

Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy. The post The Top 7 Gene-Editing Stocks to Buy for the Biggest Sci...

Other stocks mentioned: BEAM, CLLS, CLXT, EDIT, NTLA, SGMO
3 weeks ago - InvestorPlace

Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia. The post Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to So...

Other stocks mentioned: EDIT, NTLA
3 weeks ago - InvestorPlace

The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.

Other stocks mentioned: ARKG, BEAM, EDIT, GNOM, IDNA, NTLA, REGN
3 weeks ago - Zacks Investment Research

The broad markets saw a somewhat mixed start to the week with the Dow Jones Industrial Average lagging both the S&P 500 and Nasdaq.

Other stocks mentioned: AMC, CLOV, GME, SENS, WISH, WKHS
3 weeks ago - 24/7 Wall Street

So what will the stock market do today? All eyes are on gene-editing stocks like NTLA and on recovering crypto prices.

Other stocks mentioned: EDIT, NTLA
3 weeks ago - InvestorPlace

Gene editing stocks are getting a boost on Monday morning after Intellia Therapeutics said it was successful using CRISPR gene-editing therapy directed inside the body to an internal organ. The post Gen...

Other stocks mentioned: BNGO, NTLA
3 weeks ago - InvestorPlace

The broad markets saw another push higher on Thursday with the S&P 500 and Nasdaq setting new all-time highs in the session.

Other stocks mentioned: AMC, CLOV, GME, SENS, TRCH, WISH
1 month ago - 24/7 Wall Street

The short-term bottom for next-generation enterprises is in, and high multiple stocks are returning to investors' favor.

Other stocks mentioned: ARKK, CRWD, PATH, SHOP, SPLK, TSLA, TWLO ...
1 month ago - Zacks Investment Research

The Dow climbed over 1% early on Monday as a result of a strong push from industrial stocks.

Other stocks mentioned: AMC, BB, GME, PLTR, SENS
1 month ago - 24/7 Wall Street

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $127.83, marking a +0.44% move from the previous day.

1 month ago - Zacks Investment Research

The Nasdaq climbed nearly 1% on Thursday as the result of a strong push from tech stocks.

Other stocks mentioned: AMC, BB, GME, GOEV, PLTR, WOOF
1 month ago - 24/7 Wall Street

Why demand for CRISPR gene editing is increasing

YouTube video

CNBC's Meg Tirrell discusses CRISPR gene editing with one of its inventors, Jennifer Doudna, UC Berkeley biochemist.

1 month ago - CNBC Television

CRISPR Therapeutics (CRSP) signs a strategic collaboration with Capsida Biotherapeutics to develop/commercialize gene editing therapies for neurological diseases.

1 month ago - Zacks Investment Research

CRISPR Therapeutics (NASDAQ: CRSP) has signed a deal with Capsida Biotherapeutics, a gene therapy player specializing in AAV engineering, to carve out a delivery mechanism for the company's gene-editing...

1 month ago - Benzinga

- Collaboration leverages expertise and capabilities of both companies towards developing life-changing treatments for severe neurological diseases -

1 month ago - GlobeNewsWire

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, has seen a solid 26% rise over the last twenty-one trading ses...

1 month ago - Forbes

CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.

1 month ago - Zacks Investment Research

Monday's futures were relatively flat, with the Nasdaq looking the best out of the group with about a 0.2% gain.

Other stocks mentioned: CMG, KMI, WEN, AUTL, CLB, CQP, DHX ...
1 month ago - 24/7 Wall Street

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) have announced new data from Phase 1/2 clinical trials evaluating CTX001 in beta-thalassemia and sickle cell ...

Other stocks mentioned: VRTX
1 month ago - Benzinga

BOSTON & ZUG, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and CRISPR Therapeutics (Nasdaq:CRSP) today announced new data on 22 patients, with follo...

Other stocks mentioned: VRTX
1 month ago - Business Wire

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $118.91, moving -0.24% from the previous trading session.

1 month ago - Zacks Investment Research

Here are some of our experts' favorite gene editing plays for the long run.

Other stocks mentioned: EDIT, NTLA, NVTA
1 month ago - The Motley Fool

Unfortunately, this isn't an endorsement by a big drug developer.

Other stocks mentioned: NKTX
1 month ago - The Motley Fool

Some of our experts think this stock has tons of long-term potential.

1 month ago - The Motley Fool

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

They're well below peak levels set earlier this year. But they could be huge winners over the long run.

Other stocks mentioned: EXAS, TDOC, TWST
1 month ago - The Motley Fool

Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared ...

Other stocks mentioned: CERC, HZNP, JNJ, LLY, SDGR, TAK
2 months ago - InvestorPlace

CAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstracts...

2 months ago - GlobeNewsWire

Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all th...

Other stocks mentioned: NKTX
2 months ago - Benzinga

One company is setting itself apart in a crowded field.

2 months ago - The Motley Fool

Here is what you should know about investing in these life changing technologies.

Other stocks mentioned: BNTX, CHNA, CNCR, CVAC, EDIT, IBB, MRNA ...
2 months ago - Zacks Investment Research

ZUG, Switzerland and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...

2 months ago - GlobeNewsWire

ZUG, Switzerland and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...

2 months ago - GlobeNewsWire

CRISPR Therapeutics' (CRSP) earnings and revenues miss estimates in the first quarter of 2021. Focus on pipeline development.

2 months ago - Zacks Investment Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -4.14% and -89.21%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

- Granted Priority Medicines designation by the European Medicines Agency for CTX001™ for transfusion-dependent beta thalassemia (TDT)-

2 months ago - GlobeNewsWire

The Nasdaq gained ground to start the week.

Other stocks mentioned: SWKS
2 months ago - The Motley Fool

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...

Other stocks mentioned: AXSM, QURE, VYGR, RVPH
2 months ago - Benzinga

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate... [Read more...]

Industry
Biotechnology
IPO Date
Oct 19, 2016
CEO
Samarth Kulkarni
Employees
410
Stock Exchange
NASDAQ
Ticker Symbol
CRSP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 18 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is 163.11, which is an increase of 33.40% from the latest price.

Price Target
$163.11
(33.40% upside)
Analyst Consensus: Buy